In Q1 2019 costs came down, as the projects have been in a less cost consuming phase. Management confirms that the ongoing HEAL LL-37 phase 2 study is progressing according to their plan, but also that an application to regulatory authorities could be filed later this for the approval of starting a European PXL01 phase 3 trial in 2020.